Huang et al. analyzed the clonal overlap between tumor-infiltrating CD8+ T cells and circulating CD8+ T cells in melanoma patients receiving PD-1-targeted immunotherapy with pembrolizumab. This evidence concerns the gene CD8A and neoplasm.